343 related articles for article (PubMed ID: 15059267)
1. Serum levels of cartilage oligomeric matrix protein are elevated in rheumatoid arthritis, but not in inflammatory rheumatic diseases such as psoriatic arthritis, reactive arthritis, Raynaud's syndrome, scleroderma, systemic lupus erythematosus, vasculitis and Sjögren's syndrome.
Skoumal M; Haberhauer G; Feyertag J; Kittl EM; Bauer K; Dunky A
Arthritis Res Ther; 2004; 6(2):73-4. PubMed ID: 15059267
[No Abstract] [Full Text] [Related]
2. [Hemorheologic disturbances and circulating immune complexes in patients with rheumatic diseases].
Loskutova TT; Koreshkov GG; Nasonov EL; Zakharchenko VN; Larionov SM
Ter Arkh; 1989; 61(5):51-5. PubMed ID: 2781490
[No Abstract] [Full Text] [Related]
3. Serum COMP-C3b complexes in rheumatic diseases and relation to anti-TNF-α treatment.
Happonen KE; Saxne T; Geborek P; Andersson M; Bengtsson AA; Hesselstrand R; Heinegård D; Blom AM
Arthritis Res Ther; 2012 Jan; 14(1):R15. PubMed ID: 22264230
[TBL] [Abstract][Full Text] [Related]
4. Serum concentrations of cardiac troponin-I in patients with rheumatoid arthritis, systemic lupus erythematosus, primary Sjogren's syndrome and Graves' disease.
Al-Awadhi AM; Olusi S; Hasan EA; Abdullah A
Singapore Med J; 2007 Sep; 48(9):847-9. PubMed ID: 17728967
[TBL] [Abstract][Full Text] [Related]
5. [Cryoglobulinemia in rheumatic diseases].
Baranauskaĭte AA; Nasonov EL; Solov'ev SK
Klin Med (Mosk); 1991 Jun; 69(6):23-32. PubMed ID: 1774903
[No Abstract] [Full Text] [Related]
6. Abnormal structures in circulating lymphocytes from patients with systemic lupus erythematosus and related diseases.
Grrimley PM; Decker JL; Michelitch HJ; Frantz MM
Arthritis Rheum; 1973; 16(3):313-23. PubMed ID: 4708012
[No Abstract] [Full Text] [Related]
7. High prevalence of autoantibodies against the nuclear high mobility group (HMG) protein SSRP1 in sera from patients with systemic lupus erythematosus, but not other rheumatic diseases.
Santoro P; De Andrea M; Migliaretti G; Trapani C; Landolfo S; Gariglio M
J Rheumatol; 2002 Jan; 29(1):90-3. PubMed ID: 11824977
[TBL] [Abstract][Full Text] [Related]
8. Reflections in the assessment of secondary Sjogren's syndrome.
Hernández-Molina G; Avila-Casado C; Sánchez-Guerrero J
Rheumatology (Oxford); 2011 Aug; 50(8):1519-21. PubMed ID: 21672968
[No Abstract] [Full Text] [Related]
9. Increased matrix metalloproteinase-3 serum levels in rheumatic diseases: relationship with synovitis and steroid treatment.
Ribbens C; Martin y Porras M; Franchimont N; Kaiser MJ; Jaspar JM; Damas P; Houssiau FA; Malaise MG
Ann Rheum Dis; 2002 Feb; 61(2):161-6. PubMed ID: 11796404
[TBL] [Abstract][Full Text] [Related]
10. Serum pepsinogen I in rheumatic diseases. Reduced levels in Sjögren's syndrome.
Maury CP; Räsänen V; Teppo AM; Helve T; Wegelius O
Arthritis Rheum; 1982 Sep; 25(9):1059-63. PubMed ID: 6751336
[TBL] [Abstract][Full Text] [Related]
11. Erythrocyte sedimentation rate within rheumatic disease clinics.
Giacomello A; Quaratino CP; Zoppini A
J Rheumatol; 1997 Nov; 24(11):2263-5. PubMed ID: 9375897
[No Abstract] [Full Text] [Related]
12. A prospective analysis of anti-desmoglein antibody profiles in patients with rheumatoid arthritis treated with thiol compounds.
Yamamoto T; Takata-Michigami M; Hisamatsu Y; Yamamoto T; Hamada T; Fujii K; Fujimoto W; Taneichi K; Aoyama Y; Iwatsuki K
J Dermatol Sci; 2010 Sep; 59(3):170-5. PubMed ID: 20650613
[TBL] [Abstract][Full Text] [Related]
13. Sensitivity and specificity of anti-alpha-fodrin antibodies in primary Sjögren's syndrome.
Szántó A; Csípo I; Zeher M
J Rheumatol; 2005 Jan; 32(1):197; author reply 197-8. PubMed ID: 15630756
[No Abstract] [Full Text] [Related]
14. Arthritis-associated syndromes.
Osial TA; Cash JM; Eisenbeis CH
Prim Care; 1993 Dec; 20(4):857-82. PubMed ID: 8310085
[TBL] [Abstract][Full Text] [Related]
15. A critical review of the effect of levamisole in rheumatic diseases other than rheumatoid arthritis.
Rosenthal M
J Rheumatol Suppl; 1978; 4():97-100. PubMed ID: 366146
[TBL] [Abstract][Full Text] [Related]
16. Surfactant protein D (SP-D) and systemic scleroderma (SSc).
Maeda M; Ichiki Y; Aoyama Y; Kitajima Y
J Dermatol; 2001 Sep; 28(9):467-74. PubMed ID: 11603386
[TBL] [Abstract][Full Text] [Related]
17. [Basic immunologic indices and their significance in the diagnosis of rheumatic diseases. II. Analysis of immunologic indices in individual rheumatic diseases].
Timofeev VT
Revmatologiia (Mosk); 1983; (4):48-54. PubMed ID: 6366975
[No Abstract] [Full Text] [Related]
18. [Fibrin fibrinogen degradation products in the blood in systemic lupus erythematosus and other major collagen diseases].
Wysocka K; Kiczak J
Reumatologia; 1982; 20(1-2):15-21. PubMed ID: 7163659
[No Abstract] [Full Text] [Related]
19. Circulating soluble CD30 levels in primary Sjögren's syndrome, SLE and rheumatoid arthritis.
Ichikawa Y; Yoshida M; Yamada C; Horiki T; Hoshina Y; Uchiyama M
Clin Exp Rheumatol; 1998; 16(6):759-60. PubMed ID: 9844777
[No Abstract] [Full Text] [Related]
20. Expression of CD5 and CD23 on B cells of patients with rheumatoid arthritis, systemic lupus erythematosus and Sjögren's syndrome. Relationship with disease activity and treatment.
Ebo D; DeClerck LS; Bridts CH; Stevens WJ
In Vivo; 1994; 8(4):577-80. PubMed ID: 7534494
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
